397 related articles for article (PubMed ID: 15809513)
1. Nuclear survivin is a powerful novel prognostic marker in gastroenteropancreatic neuroendocrine tumor disease.
Grabowski P; Griss S; Arnold CN; Hörsch D; Göke R; Arnold R; Heine B; Stein H; Zeitz M; Scherübl H
Neuroendocrinology; 2005; 81(1):1-9. PubMed ID: 15809513
[TBL] [Abstract][Full Text] [Related]
2. Loss of nuclear p27 expression and its prognostic role in relation to cyclin E and p53 mutation in gastroenteropancreatic neuroendocrine tumors.
Grabowski P; Schrader J; Wagner J; Hörsch D; Arnold R; Arnold CN; Georgieva I; Stein H; Zeitz M; Daniel PT; Sturm I
Clin Cancer Res; 2008 Nov; 14(22):7378-84. PubMed ID: 19010853
[TBL] [Abstract][Full Text] [Related]
3. Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma.
Kleinberg L; Flørenes VA; Silins I; Haug K; Trope CG; Nesland JM; Davidson B
Cancer; 2007 Jan; 109(2):228-38. PubMed ID: 17167759
[TBL] [Abstract][Full Text] [Related]
4. Nuclear and cytoplasmic cellular distribution of survivin as survival predictor in resected non-small-cell lung cancer.
Bria E; Visca P; Novelli F; Casini B; Diodoro MG; Perrone-Donnorso R; Botti C; Sperduti I; Facciolo F; Milella M; Cecere FL; Cognetti F; Mottolese M
Eur J Surg Oncol; 2008 May; 34(5):593-8. PubMed ID: 17693049
[TBL] [Abstract][Full Text] [Related]
5. Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors.
Shida T; Kishimoto T; Furuya M; Nikaido T; Koda K; Takano S; Kimura F; Shimizu H; Yoshidome H; Ohtsuka M; Tanizawa T; Nakatani Y; Miyazaki M
Cancer Chemother Pharmacol; 2010 Apr; 65(5):889-93. PubMed ID: 19657638
[TBL] [Abstract][Full Text] [Related]
6. No prognostic impact of survivin expression in glioblastoma.
Preusser M; Gelpi E; Matej R; Marosi C; Dieckmann K; Rössler K; Budka H; Hainfellner JA
Acta Neuropathol; 2005 May; 109(5):534-8. PubMed ID: 15843906
[TBL] [Abstract][Full Text] [Related]
7. Survivin expression and its relationship with apoptosis and prognosis in nasal and paranasal sinus carcinomas.
Zhang Y; Huang D; Yu G
Acta Otolaryngol; 2005 Dec; 125(12):1345-50. PubMed ID: 16303685
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE).
Martin-Perez E; Capdevila J; Castellano D; Jimenez-Fonseca P; Salazar R; Beguiristain-Gomez A; Alonso-Orduña V; Martinez Del Prado P; Villabona-Artero C; Diaz-Perez JA; Monleon A; Marazuela M; Pachon V; Sastre-Valera J; Sevilla I; Castaño A; Garcia-Carbonero R
Neuroendocrinology; 2013; 98(2):156-68. PubMed ID: 23988576
[TBL] [Abstract][Full Text] [Related]
9. The significance of CD44 expression in gastrointestinal neuroendocrine tumors.
Lai CH; Shan YS; Sy ED; Hsieh YH; Tsai HW; Lee JC; Lin PW
Hepatogastroenterology; 2005; 52(64):1071-6. PubMed ID: 16001632
[TBL] [Abstract][Full Text] [Related]
10. P53, KI-67, CD117 expression in gastrointestinal and pancreatic neuroendocrine tumours and evaluation of their correlation with clinicopathological and prognostic parameters.
Kımıloğlu Şahan E; Erdoğan N; Ulusoy İ; Samet E; Akyıldız İğdem A; Gönüllü D
Turk J Gastroenterol; 2015 Mar; 26(2):104-11. PubMed ID: 25835106
[TBL] [Abstract][Full Text] [Related]
11. Survivin expression in intracranial ependymomas and its correlation with tumor cell proliferation and patient outcome.
Preusser M; Wolfsberger S; Czech T; Slavc I; Budka H; Hainfellner JA
Am J Clin Pathol; 2005 Oct; 124(4):543-9. PubMed ID: 16146813
[TBL] [Abstract][Full Text] [Related]
12. Expression of survivin and its spliced variants in bladder tumors as a potential prognostic marker.
Nouraee N; Mowla SJ; Ozhand A; Parvin M; Ziaee SA; Hatefi N
Urol J; 2009; 6(2):101-8. PubMed ID: 19472128
[TBL] [Abstract][Full Text] [Related]
13. Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma.
Shinohara ET; Gonzalez A; Massion PP; Chen H; Li M; Freyer AS; Olson SJ; Andersen JJ; Shyr Y; Carbone DP; Johnson DH; Hallahan DE; Lu B
Cancer; 2005 Apr; 103(8):1685-92. PubMed ID: 15742356
[TBL] [Abstract][Full Text] [Related]
14. [Neuroendocrine tumors of the gastroenteropancreatic system--reevaluation using the Capella classification].
Brüwer M; Pahlov-Nejad T; Herbst H; Senninger N; Schürmann G
Zentralbl Chir; 2003 Aug; 128(8):656-62. PubMed ID: 12931261
[TBL] [Abstract][Full Text] [Related]
15. Survivin and epidermal growth factor receptor expression in surgically treated oropharyngeal squamous cell carcinoma.
Preuss SF; Weinell A; Molitor M; Semrau R; Stenner M; Drebber U; Wedemeyer I; Hoffmann TK; Guntinas-Lichius O; Klussmann JP
Head Neck; 2008 Oct; 30(10):1318-24. PubMed ID: 18704972
[TBL] [Abstract][Full Text] [Related]
16. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors.
Sui L; Dong Y; Ohno M; Watanabe Y; Sugimoto K; Tokuda M
Int J Oncol; 2002 Aug; 21(2):315-20. PubMed ID: 12118327
[TBL] [Abstract][Full Text] [Related]
17. Survivin expression and its clinical significance in pancreatic cancer.
Lee MA; Park GS; Lee HJ; Jung JH; Kang JH; Hong YS; Lee KS; Kim DG; Kim SN
BMC Cancer; 2005 Oct; 5():127. PubMed ID: 16202147
[TBL] [Abstract][Full Text] [Related]
18. Tissue microarray analysis of the prognostic value of E-cadherin, Ki67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma.
Fromont G; Rouprêt M; Amira N; Sibony M; Vallancien G; Validire P; Cussenot O
Eur Urol; 2005 Nov; 48(5):764-70. PubMed ID: 16126329
[TBL] [Abstract][Full Text] [Related]
19. Survivin, a member of the inhibitors of apoptosis family, is down-regulated in breast carcinoma effusions.
Kleinberg L; Flørenes VA; Nesland JM; Davidson B
Am J Clin Pathol; 2007 Sep; 128(3):389-97. PubMed ID: 17709312
[TBL] [Abstract][Full Text] [Related]
20. Angiopoietin-2 promotes disease progression of neuroendocrine tumors.
Detjen KM; Rieke S; Deters A; Schulz P; Rexin A; Vollmer S; Hauff P; Wiedenmann B; Pavel M; Scholz A
Clin Cancer Res; 2010 Jan; 16(2):420-9. PubMed ID: 20068079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]